منابع مشابه
Dosimetric comparison of conventional and field-in-field techniques in early stage breast cancer radiotherapy
Introduction: Breast conserving surgery followed by adjuvant radiotherapy (RT) of the whole breast is accepted as the treatment of choice in early stage breast cancer. Due to breast irregularities, it is difficult to access homogenous dose distribution with conventional techniques. Currently, it is possible to use varied breast irradiation techniques, such as field- in-field (F...
متن کاملRapid Health Technology Assessment of Oncotype DX in Patients with Early-Stage Breast Cancer
Introduction: Breast cancer is the most common cancer in women. Patients are treated with chemotherapy initially, and if not chemically treated, the risk of recurrence of the disease increases yearly. Therefore, methods for identifying patients for whom chemotherapy would be most beneficial are very important. The Oncotype DX test is a prognostic assay that predicts the likelihood of breast can...
متن کامل[Adjuvant chemotherapy of early stage breast cancer].
UNLABELLED Adjuvant systemic therapy reduces the likelihood of both local and distant relapses by eradicating micrometastases. AIM To survey the adjuvant treatment of early breast cancer. METHODS Author presents an overview of the systemic therapy of early breast cancer based on relevant literature and own experiences. RESULTS Three systemic treatment modalities are widely used as adjuvan...
متن کاملImproving outcomes in early-stage breast cancer.
Early-stage breast cancer is a prevalent malignancy that continues to cause a significant number of cancer-related deaths each year. Current evidence points to suboptimal care in patients with early-stage breast cancer, especially with regard to physician use of guideline-recommended care. Such appropriate treatment regimens as breast-conserving therapy and adjuvant therapy (including radiation...
متن کاملTrastuzumab (herceptin) for early-stage breast cancer.
Breast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free and overall survivals. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, has been shown to benefit patients who have HER2-positive metastatic breast cancer, and recently, the results of five ad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2006
ISSN: 0276-2234
DOI: 10.1097/01434893-200601000-00007